The main line of inquiry in Dr. Elyaman’s laboratory is to understand how regions of the human genome containing risk alleles alter the function of T cell lymphocytes and, in doing so, increases an individual’s risk of developing autoimmune and/or neurodegenerative diseases (Orent et al Hum Mol. Genet. 2016; Kaskow et al, Neurol. Neuroimmunol. Neuroinflamm. 2017). Another line of research in Dr. Elyaman’s lab is to understand the role of adaptive immune cells in aging and neurological diseases including Alzheimer’s disease and epilepsy and how they interact with central nervous system (CNS) resident innate cells using co-culture models of human effector/regulatory T cells and microglia-like cells (Ryan et al, Sci Transl. Med. 2017). As the co-director for basic research in the new Center for Translational and Computational Neuro-immunology (CTCN), his goal is to translate research findings into novel clinical tools to enhance drug discovery efforts using human and murine systems.

Education and Training:

Maitrise in Molecular and Cell Biology, University of Limoges, France
DEA (Master) in Toxicology, University of René Descartes, Paris, France
PhD in Neuroscience, University of Limoges, France
Fellowship, Brigham and Women's Hospital/Harvard Medical School